中文摘要：

目的 鉴定人白细胞抗原（HLA）-A＊0201限制性HCV-CTL表位.方法 基于RANKpep和SYFPEITHI细胞表位预测软件预测结果,选择合成6条候选CTL表位.研究候选CTL表位肽与T2细胞表达的HLA-A＊0201分子的亲和力,进一步采用酶联免疫斑点实验（ELISPOT）和细胞内细胞因子染色（ICS）实验研究HLA-A＊0201高亲和力肽在HLA-A＊0201阳性HCV感染者的外周血单个核细胞（PBMC）中刺激CTL反应情况.结果 在6条候选CTL表位肽中,肽C_181（LLSCLTTPV）和NS2_172（VLQAGLIRV）与HLA-A＊0201分子有高亲和力,其亲和力随肽浓度增加而升高.在10例HLA-A＊0201阳性HCV-1b感染者每1×105PBMC中,肽C_181和NS2_172刺激后,特异性分泌IFN-γ细胞的斑点形成细胞数（SFC）分别为0～19和0～20.肽C_181和NS2_172特异性IFN-γ＋CD8＋T淋巴细胞占CD8＋T淋巴细胞的比例分别为0.006%～0.065%和0.005%～0.080%.结论 肽C_181（LLSCLTTPV）和NS2_172（VLQAGLIRV）为HLA-A＊0201 限制性HCV-CTL表位.

英文摘要：

Objective To identify human leucocyte antigen （HLA）-A＊ 0201-restricted hepatitis C virus （HCV）-cytotoxic T lymphocyte （CTL） epitopes. Methods Based on the prediction results of RANKpep and SYFPEITHI prediction programs, six candidate CTL epitopes were selected and synthesized. The affinity of candidate CTL epitopes to HLA-A＊ 0201 molecules of T2 cells was explored. Subsequently, enzyme-linked immunosorbent spot （ELISPOT） assay and intracellular cytokine staining （ICS） were utilized to determine whether candidate CTL epitopes could induce the recall positive response in peripheral blood mononuclear cells （PBMC） of HLA-A＊ 0201 positive HCV-1b-infected patients. Results Among six candidate CTL epitopes, peptides C_181（LLSCLTTPV） and NS2_172 （VLQAGLIRV） had high affinity to HLA-A＊ 0201 molecules. Moreover, the affinity was proportional to the concentration of peptide. Furthermore, among ten HLA-A＊ 0201 positive HCV-1b-infected patients, the frequencies of C_181 and NS2_172-specific interferon （IFN）-γ-producing cells were 0-19 spots forming cells （SFC）/1 × 105 PBMC and 0-20 SFC/1 × 105 PBMC, respectively.The percentages of C_ 181 and NS2_172-specific IFN-γ＋ CD8＋ T lymphocytes in total CD8＋ T lymphocytes were 0.006%-0.065% and 0.005%-0.080%, respectively. Conclusion Peptides C_181 （LLSCLTTPV） and NS2_172 （VLQAGLIRV） are identified as novel HLA-A＊ 0201-restricted HCV-CTL epitopes.